- Cipla’s net income was 9.39 billion rupees, that’s a year-on-year increase of 79%. That’s better than the estimated 8.63 billion rupees.
- The revenue was 61.6 billion rupees, which represents an annual increase of 7.3%. This is slightly lower than the estimated 62.34 billion rupees.
- Total costs incurred by the company were 51.5 billion rupees, an increase of 4% from the previous year.
- The company had other incomes totaling 2.49 billion rupees, up by a staggering 84% from the prior year.
- A dividend of 13 rupees per share was announced by the company.
- There were 25 recommendations to buy the company’s stock, 7 holds, and 6 sells.
- All these figures and year-on-year comparisons are based on the values reported by the company in its original disclosures.
Cipla Ltd on Smartkarma
Analyst coverage of Cipla Ltd on Smartkarma shows positive sentiment from Tina Banerjee in her recent report titled “Cipla (CIPLA IN): Q3FY24 Result- Continued Growth Trajectory Across Key Markets; Positive Outlook“. The report highlights Cipla’s strong Q3FY24 performance, with a 14% YoY sales growth and a 24.2% EBITDA margin. Key markets like the US business achieved record-high sales, with North America reporting the highest-ever revenue of $230M. India revenue also saw a 12% YoY increase, thanks to growth in branded prescriptions, trade generics, and consumer health. The full-year EBITDA margin is trending towards the higher end of the guidance range, indicating a positive outlook for the company.
Tina Banerjee‘s analysis points out that Cipla’s Peptide product launches in the U.S. are set to bolster its near-term growth prospects. With double-digit growth across India, North America, and South Africa, Cipla Ltd is positioned well for continued success as it moves forward. The report provides valuable insights into the company’s financial performance and market positioning, offering investors a comprehensive view to make informed decisions about their investment in Cipla Ltd.
A look at Cipla Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead, Cipla Ltd, a company that manufactures and sells pharmaceutical and personal care products, shows a promising long-term outlook based on the Smartkarma Smart Scores. With above-average scores in Dividend, Resilience, and Momentum, Cipla Ltd demonstrates strong financial health and consistent performance. These factors indicate the company’s ability to weather market challenges and maintain steady growth over time. While the Value and Growth scores are slightly lower, the overall picture suggests a stable and reliable investment opportunity.
Cipla Ltd‘s focus on producing a wide range of pharmaceutical products across various therapeutic areas positions it well for sustained success in the industry. The company’s commitment to providing essential healthcare solutions is reflected in its strong dividend payouts and robust performance metrics. With a solid foundation in place, Cipla Ltd appears set to continue delivering value to investors and maintaining its position as a reputable player in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
